Apyx Medical Q4 2022 revenue down 25% to $12.6M; net loss $6.0M; guides 2023 rev $58-61M

Apyx Medical Corp

Q4 total revenue $12.6M (-25% YoY); Advanced Energy segment $10.5M (-30% YoY); OEM $2.1M (+15% YoY).
FY2022 net loss $23.2M ($0.67/share) vs $15.2M in 2021; adjusted EBITDA loss $15.4M vs $8.8M.
Introduces FY2023 guidance: total revenue $58-61M (30-37% growth); net loss ~$14M vs $23.2M in 2022.
Post-quarter: FDA 510(k) clearance for Renuvion APR Handpiece (Feb 27); $35M credit facility with MidCap Financial.
CEO cites FDA Safety Communication disruption; expects >35% Advanced Energy growth in 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Apyx Medical Corp reported full year ended December 31, 2022 results: revenue $44.5 million, net income Net loss attributable to stockholders of $23.2 million. Guidance initiated.

Period: full year ended December 31, 2022
Revenue: $44.5 million
Net income: Net loss attributable to stockholders of $23.2 million
Guidance: initiated
Result: reported results

Exact text from the filing

the fourth quarter of 2021. • Adjusted EBITDA loss of $4.1 million, compared to $0.3 million for the fourth quarter of 2021. Full Year 2022 Financial Summary: • Total revenue of $44.5 million, down 8% year-over-year. ◦ Advanced Energy revenue of $36.8 million, down 14% year-over-year. ◦ OEM revenue of $7.7 million, up 39% year-over-year. • Net loss attributable to

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Apyx Medical Corp reported for the fourth quarter and year ended December 31, 2022 results: revenue $12.6 million, net income Net loss attributable to stockholders of $6.0 million.

Period: for the fourth quarter and year ended December 31, 2022
Revenue: $12.6 million
Net income: Net loss attributable to stockholders of $6.0 million
Result: reported results

Exact text from the filing

full year ended December 31, 2022, and introduced financial expectations for the full year ending December 31, 2023. Fourth Quarter 2022 Financial Summary : • Total revenue of $12.6 million, down 25% year-over-year. ◦ Advanced Energy revenue of $10.5 million, down 30% year-over-year. ◦ OEM revenue of $2.1 million, up 15% year-over-year. • Net loss attributable to

View on SEC.gov

Browse all earnings releases →

Apyx Medical Corp filing history →

Source: SEC EDGAR

accession 0000719135-23-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.